表 2.7.4.4-1-1　バイタルサイン　拡張期血圧（02CLL III 試験）（続き）

Astellas Pharma GmbH, Germany / Sequence 0000

ribosepharm GmbH　　Bendamustine Hydrochloride versus Chlorambucil　　- Page 1921
Report　　in patients with B-CLL requiring therapy　　24/04/2007
Final Analysis

Table 20.3
Vital signs
Systolic blood pressure [mmHg] - Summary statistics by visit and treatment

Safety Population

Visit / Summary statistics	BEN (A) (N = 154) Actual	BEN (A) (N = 154) Change	CLB (B) (N = 144) Actual	CLB (B) (N = 144) Change	Difference 1 B - A
Cycle 6					
n	95	90	75	74	
Mean (SD)	135.5 (15.0)	-0.9 (15.3)	132.2 (15.1)	-3.1 (15.6)	-2.60 (12.10)
95% CL	[132.5; 138.6]	[-4.2; 2.3]	[128.7; 135.6]	[-6.7; 0.5]	[-6.35; 1.15]
Min-Max	100.0 - 170.0	-50.0 - 30.0	95.0 - 200.0	-50.0 - 30.0	F = 1.8770
Median	135.0	0.0	130.0	0.0	P = 0.1726
Q1-Q3	125.0 - 145.0	-10.0 - 10.0	120.0 - 140.0	-15.0 - 10.0	
Follow-up 1					
n	71	68	43	42	
Mean (SD)	133.4 (12.2)	-1.3 (14.9)	132.3 (13.6)	-1.0 (17.5)	-0.41 (11.12)
95% CL	[130.5; 136.3]	[-4.9; 2.3]	[128.2; 136.5]	[-6.4; 4.5]	[-4.74; 3.92]
Min-Max	110.0 - 162.0	-40.0 - 42.0	105.0 - 170.0	-60.0 - 30.0	F = 0.0354
Median	135.0	0.0	130.0	0.0	P = 0.8512
Q1-Q3	125.0 - 140.0	-10.0 - 10.0	120.0 - 140.0	-10.0 - 10.0	
Follow-up 2					
n	54	53	22	22	
Mean (SD)	138.2 (18.2)	1.9 (18.0)	131.8 (17.6)	-1.0 (14.3)	-4.50 (15.61)
95% CL	[133.3; 143.2]	[-3.0; 6.9]	[124.0; 139.6]	[-7.3; 5.3]	[-12.43; 3.44]
Min-Max	97.0 - 186.0	-40.0 - 54.0	90.0 - 170.0	-30.0 - 30.0	F = 1.2770
Median	130.0	0.0	130.0	0.0	P = 0.2622
Q1-Q3	130.0 - 150.0	-10.0 - 10.0	120.0 - 140.0	-10.0 - 10.0	
Follow-up 3					
n	40	38	11	11	
Mean (SD)	136.8 (15.3)	1.6 (15.4)	132.7 (25.6)	5.5 (14.6)	1.36 (14.48)
95% CL	[131.8; 141.7]	[-3.5; 6.6]	[115.5; 149.9]	[-4.3; 15.2]	[-8.84; 11.56]
Min-Max	110.0 - 186.0	-40.0 - 41.0	90.0 - 180.0	-10.0 - 40.0	F = 0.0717
Median	133.0	0.0	130.0	0.0	P = 0.7901
Q1-Q3	125.0 - 145.0	-5.0 - 10.0	110.0 - 150.0	-5.0 - 10.0	
Follow-up 4					
n	34	31	5	5	
Mean (SD)	139.4 (16.3)	2.7 (17.7)	128.8 (15.3)	2.4 (21.9)	-7.56 (15.96)
95% CL	[133.7; 145.0]	[-3.8; 9.2]	[109.8; 147.8]	[-24.8; 29.6]	[-28.81; 8.68]
Min-Max	110.0 - 175.0	-40.0 - 45.0	105.0 - 144.0	-15.0 - 37.0	F = 0.8975
Median	135.0	5.0	130.0	-5.0	P = 0.3503
Q1-Q3	130.0 - 150.0	-10.0 - 10.0	125.0 - 140.0	-15.0 - 10.0	

Baseline=Cycle 1/Day 1 if data at screening examination not available
For change from baseline only patients with pairwise available visits are considered
Differences between groups and 95% confidence limits are adjusted for baseline values
(Least square means from analysis of variance)
Data after follow-up 4 are not displayed

d.s.h. statistical services gmbh

Ribomustin Test 1 MS/ 5.3.5.1.1 CLL Mundipharma 02CLLIII-ID900 /p10852

引用:CSR Appendix14 Table20.3

表 2.7.4.4-1-2　バイタルサイン　拡張期血圧（02CLL IIIFU）

Visit	BEN (A) (N = 161)			CLB (B) (N = 151)			Difference [1] B – A [95% CI]
	N	Actual	Change	N	Actual	Change	
Baseline	152	79.1 (9.8)		139	78.6 (8.9)		
Cycle 2	129	77.4 (10.0)	-1.8 (9.3)	128	78.5 (9.7)	-0.2 (9.5)	1.34 (8.46) [-0.80; 3.48]
Cycle 3	118	77.6 (8.9)	-1.9 (10.0)	121	75.9 (10.5)	-3.2 (10.0)	-1.70 (8.65) [-3.97; 0.57]
Cycle 4	114	78.1 (9.9)	-1.0 (10.8)	107	77.3 (8.0)	-1.7 (10.7)	-0.99 (8.58) [-3.32; 1.34]
Cycle 5	109	77.5 (11.0)	-1.5 (10.4)	94	77.6 (7.9)	-1.2 (9.6)	-0.17 (8.74) [-2.67; 2.33]
Cycle 6	101	78.8 (8.7)	-0.6 (10.7)	82	78.8 (8.3)	-0.4 (9.5)	-0.12 (8.06) [-2.54; 2.29]

引用: 02CLL III FU　Table 76

表 2.7.4.2.2-2-1　バイタルサイン 収縮期血圧（02CLLⅢ試験）

ribosepharm GmbH　　Bendamustine Hydrochloride versus Chlorambucil　　- Page 1922
Report　　in patients with B-CLL requiring therapy　　24/04/2007
Final Analysis

Table 20.4
Vital signs
Diastolic blood pressure [mmHg] - Summary statistics by visit and treatment

Safety Population

Visit / Summary statistics	BEN (A) (N = 154) Actual	BEN (A) (N = 154) Change	CLB (B) (N = 144) Actual	CLB (B) (N = 144) Change	Difference 1 B - A
Baseline					
n	146		133		
Mean (SD)	79.3 (9.9)		78.7 (8.9)		
95% CL	[77.6; 80.9]		[77.2; 80.2]		
Min-Max	48.0 - 110.0		55.0 - 105.0		
Median	80.0		80.0		
Q1-Q3	70.0 - 85.0		70.0 - 85.0		
Cycle 2					
n	123	118	121	114	
Mean (SD)	77.3 (10.1)	-2.0 (9.3)	78.4 (9.9)	-0.3 (9.5)	1.28 (8.50)
95% CL	[75.5; 79.1]	[-3.7; -0.3]	[76.7; 80.2]	[-2.1; 1.4]	[-0.92; 3.48]
Min-Max	50.0 - 110.0	-30.0 - 25.0	60.0 - 110.0	-25.0 - 30.0	F = 1.3068
Median	80.0	0.0	80.0	0.0	P = 0.2542
Q1-Q3	70.0 - 80.0	-10.0 - 5.0	70.0 - 85.0	-5.0 - 5.0	
Cycle 3					
n	115	110	115	108	
Mean (SD)	77.5 (9.0)	-2.1 (10.1)	75.9 (10.7)	-3.3 (9.8)	-1.61 (8.68)
95% CL	[75.8; 79.1]	[-4.0; -0.1]	[73.9; 77.8]	[-5.2; -1.4]	[-3.93; 0.71]
Min-Max	55.0 - 100.0	-30.0 - 25.0	40.0 - 105.0	-40.0 - 20.0	F = 1.8807
Median	80.0	0.0	80.0	0.0	P = 0.1717
Q1-Q3	70.0 - 81.0	-10.0 - 5.0	70.0 - 80.0	-10.0 - 0.0	
Cycle 4					
n	110	106	100	96	
Mean (SD)	78.0 (10.0)	-1.2 (10.9)	77.3 (8.2)	-1.7 (10.8)	-0.92 (8.78)
95% CL	[76.1; 79.9]	[-3.2; 0.9]	[75.7; 78.9]	[-3.9; 0.5]	[-3.34; 1.51]
Min-Max	55.0 - 120.0	-30.0 - 35.0	59.0 - 100.0	-25.0 - 25.0	F = 0.5553
Median	80.0	0.0	80.0	0.0	P = 0.4571
Q1-Q3	70.0 - 88.0	-10.0 - 5.0	70.0 - 80.0	-10.0 - 5.0	
Cycle 5					
n	103	98	85	81	
Mean (SD)	78.0 (10.9)	-1.4 (10.6)	77.7 (8.1)	-0.9 (9.7)	-0.20 (8.91)
95% CL	[75.8; 80.1]	[-3.5; 0.7]	[76.0; 79.5]	[-3.1; 1.2]	[-2.84; 2.45]
Min-Max	56.0 - 120.0	-20.0 - 35.0	54.0 - 100.0	-30.0 - 25.0	F = 0.0219
Median	80.0	-4.5	80.0	0.0	P = 0.8824
Q1-Q3	70.0 - 80.0	-10.0 - 5.0	70.0 - 85.0	-10.0 - 5.0	

Baseline=Cycle 1/Day 1 if data at screening examination not available
For change from baseline only patients with pairwise available visits are considered
Differences between groups and 95% confidence limits are adjusted for baseline values
(Least square means from analysis of variance)
Data after follow-up 4 are not displayed

d.s.h. statistical services gmbh

Ribomustin Test 1 MS/ 5.3.5.1.1 CLL Mundipharma 02CLLIII-ID900 /p10853

引用:CSR Appendix14 Table20.4